Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics

References

• Ajmal, A., Joffe, H., & Nachtigall, L. B. (2014). Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics, 55, 29–36. doi:10.1016/j.psym.2013.08.008
   PubMed Web of Science ®Google Scholar
• Berinder, K., Akre, O., Granath, F., & Hulting, A. L. (2011). Cancer risk in hyperprolactinemia patients: a population-based cohort study. European Journal of Endocrinology, 165, 209–215. doi:10.1530/EJE-11-0076
   PubMed Web of Science ®Google Scholar
• Bushe, C. J., Bradley, A., & Pendlebury, J. (2010). A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem, 47, 292–300. doi:10.1258/acb.2010.010025
   PubMed Web of Science ®Google Scholar
• Bushe, C., Shaw, M., & Peveler, R. C. (2008). A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology (Oxford, England), 22, 46–55. doi:10.1177/0269881107088435
   PubMedGoogle Scholar
• Chahal, J., & Schlechte, J. (2008). Hyperprolactinemia. Pituitary, 11, 141–146. doi:10.1007/s11102-008-0107-5
   PubMed Web of Science ®Google Scholar
• Cookson, J., Hodgson, R., & Wildgust, H. J. (2012). Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. Journal of Psychopharmacology, 26, 42–51. doi:10.1177/0269881112442016
   PubMed Web of Science ®Google Scholar
• Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M. (2016). The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence. The Journal of Clinical Psychiatry, 77, 1–24. doi:10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• El-Sayeh, H. G., Morganti, C., & Adams, C. E. (2006). Aripiprazole for schizophrenia. Systematic review. The British Journal of Psychiatry : The Journal of Mental Science, 189, 102–108. doi:10.1192/bjp.189.2.102
   PubMed Web of Science ®Google Scholar
• Ereshefsky, L., & Mascarenas, C. A. (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Journal of Clinical Psychiatry, 64, 18–23.
   PubMed Web of Science ®Google Scholar
• Fitzgerald, P., & Dinan, T. G. (2008). Prolactin and dopamine: What is the connection? A review article. Journal of Psychopharmacology (Oxford, England), 22, 12–19. doi:10.1177/0269216307087148
   PubMedGoogle Scholar
• Fleischhacker, W. W., Gopal, S., Lane, R., Gassmann-Mayer, C., Lim, P., Hough, D., … Eerdekens, M. (2012). A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. International Journal of Neuropsychopharmacology, 15, 107–118. doi:10.1017/S1461145711001076
   PubMed Web of Science ®Google Scholar
• Grigg, J., Worsley, R., Thew, C., Gurvich, C., Thomas, N., & Kulkarni, J. (2017). Antipsychotic-induced hyperprolactinemia: Synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl), 234, 3279–3297. doi:10.1007/s00213-017-4730-6
   PubMed Web of Science ®Google Scholar
• Halperin Rabinovich, I., Camara Gomez, R., Garcia Mouriz, M., & Ollero Garcia-Agullo, D. (2013). Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición, 60, 308–319. doi:10.1016/j.endoen.2012.11.009
   PubMedGoogle Scholar
• Houston, J. P., Fijal, B., Heinloth, A. N., & Adams, D. H. (2010). Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Research, 175, 171–172. doi:10.1016/j.psychres.2009.06.014
   PubMed Web of Science ®Google Scholar
• Ittig, S., Studerus, E., Heitz, U., Menghini-Muller, S., Beck, K., Egloff, L., … Riecher-Rossler, A. (2017). Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophr Res, 189, 111–116. doi:10.1016/j.schres.2017.02.010
   PubMed Web of Science ®Google Scholar
• Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003). Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology, 28, 55–68. doi:10.1016/S0306-4530(02)00127-0
   PubMed Web of Science ®Google Scholar
• Kusumi, I., Boku, S., & Takahashi, Y. (2015). Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry and Clinical Neurosciences, 69, 243–258. doi:10.1111/pcn.12242
   PubMed Web of Science ®Google Scholar
• Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., … Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951–962. doi:10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Mallikaarjun, S., Kane, J. M., Bricmont, P., McQuade, R., Carson, W., Sanchez, R., … Fleischhacker, W. W. (2013). Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia Research, 150, 281–288. doi:10.1016/j.schres.2013.06.041
   PubMed Web of Science ®Google Scholar
• McEvoy, J. P. (2006). Risks versus benefits of different types of long-acting injectable antipsychotics. Journal of Clinical Psychiatry, 67, 15–18.
   PubMed Web of Science ®Google Scholar
• Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. (2011). Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 96, 273–288. doi:10.1210/jc.2010-1692
   PubMed Web of Science ®Google Scholar
• Meng, M., Li, W., Zhang, S., Wang, H., Sheng, J., Wang, J., & Li, C. (2015). Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Archives Psychiatry, 27, 4–17. doi:10.11919/j.issn.1002-0829.215014
   PubMedGoogle Scholar
• Montejo, A. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., … Vieta, E. (2017). Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Frontiers in Neuroendocrinology, 45, 25–34. doi:10.1016/j.yfrne.2017.02.003
   PubMed Web of Science ®Google Scholar
• Montejo, A. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., … Vieta, E. (2016). Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Revista de Psiquiatrí́a y Salud Mental, 9, 158–173. doi:10.1016/j.rpsmen.2016.06.001
   PubMed Web of Science ®Google Scholar
• Newcomer, J. W. (2007). Metabolic syndrome and mental illness. The American Journal of Managed Care, 13, S170–S177.
   PubMed Web of Science ®Google Scholar
• Pandina, G., Lane, R., Gopal, S., Gassmann-Mayer, C., Hough, D., Remmerie, B., & Simpson, G. (2011). A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 218–226. doi:10.1016/j.pnpbp.2010.11.008
   PubMed Web of Science ®Google Scholar
• Perez-Iglesias, R., Mata, I., Martinez-Garcia, O., Garcia-Unzueta, M. T., Amado, J. A., Valdizan, E. M., … Crespo-Facorro, B. (2012). Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. Journal of Clinical Psychopharmacology, 32, 804–808. doi:10.1097/JCP.0b013e318272688b
   PubMed Web of Science ®Google Scholar
• Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014). The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs, 28, 421–453. doi:10.1007/s40263-014-0157-3
   PubMed Web of Science ®Google Scholar
• Ranjbar, F., Sadeghi-Bazargani, H., Niari Khams, P., Arfaie, A., Salari, A., & Farahbakhsh, M. (2015). Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatric Disease and Treatment, 11, 549–555. doi:10.2147/NDT.S69088
   PubMed Web of Science ®Google Scholar
• Riecher-Rossler, A., Rybakowski, J. K., Pflueger, M. O., Beyrau, R., Kahn, R. S., Malik, P., & Fleischhacker, W. W. (2013). Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychological Medicine, 43, 2571–2582. doi:10.1017/S0033291713000226
   PubMed Web of Science ®Google Scholar
• Safer, D. J., Calarge, C. A., & Safer, A. M. (2013). Prolactin serum concentrations during aripiprazole treatment in youth. Journal of Child and Adolescent Psychopharmacology, 23, 282–289. doi:10.1089/cap.2012.0062
   PubMed Web of Science ®Google Scholar
• Sáiz, J., Bobes, J., Ruiloba, V., Ubago, G., & García-Portilla, M. P. (2008). Grupo de Trabajo sobre la Salud Física del Paciente con Esquizofrenia. Consenso Sobre la Salud Física Del Paciente Con Esquizofrenia de Las Sociedades Españolas de Psiquiatría y de Psiquiatría Biológica. Actas Esp Psiquiatr, 36, 251–264.
   Google Scholar
• Segal, M., Avital, A., Rojas, M., Hausvater, N., Sandbank, S., Liba, D., … Weizman, A. (2004). Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. Psychiatry Research, 127, 227–235. doi:10.1016/j.psychres.2004.01.010
   PubMed Web of Science ®Google Scholar
• Serri, O., Chik, C. L., Ur, E., & Ezzat, S. (2003). Diagnosis and management of hyperprolactinemia. CMAJ : Canadian Medical Association Journal = Journal de L'association Medicale Canadienne, 169, 575–581.
   PubMed Web of Science ®Google Scholar
• Solgaard, T., Kistrup, K., Aaes-Jorgensen, T., & Gerlach, J. (1994). Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum Effective Dose and Corresponding Serum Levels. Pharmacopsychiatry, 27, 119–123. doi:10.1055/s-2007-1014290
   Google Scholar
• Yasui-Furukori, N., Saito, M., Nakagami, T., Sugawara, N., Sato, Y., Tsuchimine, S., … Kaneko, S. (2010). Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34, 537–540. doi:10.1016/j.pnpbp.2010.02.014
   PubMed Web of Science ®Google Scholar
• Ziadi Trives, M., Bonete Llacer, J. M., Garcia Escudero, M. A., & Martinez Pastor, C. J. (2013). Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. Journal of Clinical Psychopharmacology, 33, 538–541. doi:10.1097/JCP.0b013e3182970431
   PubMed Web of Science ®Google Scholar